Multiple Myeloma Minimal Residual Disease (MMRD)

Civil Hospices of Lyon

Status: Completed

Conditions: Multiple Myeloma

Treatments: Biological: blood samples and bone marrow aspirates will be collected

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02627261

69HCL15_0316

Details and patient eligibility

About

Three methods including flow cytometry, next generation sequencing and determination of circulating tumor cells will be performed at different time points in patients with previously undiagnosed multiple myeloma in order to determine the most sensitive method to detect residual disease

Enrollment: 48 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥ 18 years
• previously undiagnosed myeloma
• eligible for high dose therapy and bone marrow transplantation
• signed consent

Exclusion criteria

• ongoing therapy for another neoplasia
• Patients with other hematologic malignancies,
• patients deprived of liberty for administrative or judicial reasons
• previously treated for myeloma

Trial design

48 participants in 1 patient group

patients with multiple myeloma

Description:

blood samples and bone marrow aspirates will be collected in patients at different time point

Treatment:

Biological: blood samples and bone marrow aspirates will be collected